Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).

Seidel, C; Busch, J; Weikert, S; Steffens, S; Bokemeyer, C; Grünwald, V

Seidel, C; Busch, J; Weikert, S; Steffens, S; Bokemeyer, C; Grünwald, V.

Affiliation

Seidel C; Department of Oncology, Hematology and Bone Marrow Transplantation with section of Pneumology, University Medical Center Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.

Br J Cancer ; 109(12): 2998-3004, 2013 Dec 10.

Article in En | MEDLINE | ID: mdl-24169357

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma, Renal Cell/drug therapy; Carcinoma, Renal Cell/pathology; Kidney Neoplasms/drug therapy; Kidney Neoplasms/pathology; Vascular Endothelial Growth Factor A/metabolism; Angiogenesis Inhibitors/adverse effects; Angiogenesis Inhibitors/therapeutic use; Antineoplastic Agents/adverse effects; Carcinoma, Renal Cell/metabolism; Disease-Free Survival; Female; Humans; Kidney Neoplasms/metabolism; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors/adverse effects; Protein Kinase Inhibitors/therapeutic use; Survival Analysis; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Vascular Endothelial Growth Factor A / Kidney Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2013 Document type: Article

Fulltext

XML

PubMed Links

Search on Google